TONIX PHARMACEUTICALS HOLDING CORP. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 0.40% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-12
- TONIX PHARMACEUTICALS HOLDING CORP. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was 0.40%.
- TONIX PHARMACEUTICALS HOLDING CORP. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2019 was 0.00%, a 100.00% decline from fiscal 2018.
- TONIX PHARMACEUTICALS HOLDING CORP. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2018 was 0.10%, a 0.00% change from fiscal 2017.
- TONIX PHARMACEUTICALS HOLDING CORP. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2017 was 0.10%, a 0.00% change from fiscal 2016.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 0.40% 10-K · filed 2026-03-12 | |
| 2019-12-31 | 0.00% 10-K · filed 2020-03-24 | |
| 2018-12-31 | 0.10% 10-K · filed 2020-03-24 | |
| 2017-12-31 | 0.10% 10-K · filed 2019-03-18 | |
| 2016-12-31 | 0.10% 10-K · filed 2018-03-09 | |
| 2015-12-31 | 0.20% 10-K · filed 2017-04-13 | |
| 2014-12-31 | 0.30% 10-K · filed 2016-03-03 | |
| 2013-12-31 | 6.70% 10-K · filed 2016-03-03 | |
| 2012-12-31 | 5.00% 10-K · filed 2014-03-28 | 13.90% 10-K · filed 2013-03-11 |
| 2011-12-31 | 5.00% 10-K/A · filed 2013-11-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |